Copy
Construction tech market map. Pharma exits. Ed tech startups to watch.

Quid pro quo

Hi there,

Yesterday, we highlighted a post by McSweeney's about a startup that only hires 23 year olds and which thinks profits are lame and boring like old people.

Today, The Blurb features the great writing of @sarahcpr who asks:



We'll share some highlights from Sarah's post below, but first, some CB Insights data goodness.

Building blocks

We identified 100+ startups working in construction tech, and categorized them into a market map spanning 13 key emerging categories and subcategories, including marketplaces, monitoring and safety, and design technologies.



While on the topic

With all the great reporting recently that has highlighted specific examples of the harassment women in tech face, we want to ask you all whether you think things are really going to change this time.



In talking to folks in the industry recently, this issue comes up frequently and I've been struck with 3 basically distinct schools of thought on how this will all play out.

#1 - Nothing is going to change. The half-life of outrage is very short now. Some other scandal will happen that will distract us from this. In the meantime, folks will do superficial things (sign pledges, write Medium posts, express outrage on Twitter) but nothing foundational is really going to change.

#2 - This time might be different, but it'll be important that more stories keep coming out to keep this top of mind and keep the pressure on. Else, things will go back to business as usual soon enough or another outrage/scandal will replace this.

#3 - This time is really different. These stories and revelations have woken people up, and we'll be seeing meaningful change as a result.

So what do you think? (Click to vote)


Nothing is going to really change
Feels different. But we'll need more stories to keep pressure on
This time really is different. We'll see meaningful change


Pharm-to-exit

We analyzed M&A and IPO activity since 2012 among private pharma companies. 2017 has so far seen 83 exits of pharma companies.



We'll be diving deeper into this subject on Thursday during our Pulse of Pharma briefing. Sign up here.

More from Brad

Sarah Cooper's aforementioned post has some gems. 

Here's one:



And here's another:




The future of learning

We identified 15 early-stage ed tech startups to watch in diverse categories. All of the companies are early-stage startups (seed/angel or Series A), including SnapAsk below.




Rich people are so weird



The Industry Standard

CB Insights data is the most trusted by those in the industry and the media. A few recent hits.

Bloomberg. Shira Ovide (@shiraovide) writes about money flowing into the startup system and a slowdown in IPOs and references the CB Insights Unicorn Tracker.

Reuters. Heather Somerville (@heathersomervil) on Jawbone's demise with a reference to CB Insights investment data.

VentureBeat. Paddy Cosgrave (@paddycosgrave) reports on AI in China and cites CB Insights investment data.


I love you.

Anand

@asanwal

P.S. Next Tuesday, join us for a discussion on trends in capital markets tech. We'll save you a spot.

100+ startups transforming the construction industry

The construction tech industry spans emerging categories such as collaboration software, marketplaces, and frontier tech applications. See the market map.
Tweet this
 

Pharma IPO market picks back up, as overall exits decline

Notable exits of 2017 so far include the acquisition of Delinia by Celgene and the IPO of Jounce Therapeutics. See the data.
Tweet this
 

15 early-stage ed tech companies to watch

Many of these ed tech companies focus on connecting learners and teachers, offering access to experts, and keeping learners entertained. See the list.
Tweet this
 

The Blurb

A curated mix of articles worth sharing.

Why do all these women keep accusing me of harassment? Sarah Cooper (@sarahcpr) offers a satirical view into the life of Brad, a hot shot VC.
Medium

a16z podcast. The golden era of productivity, retail, and supply chains.
a16z

Will private equity eat itself? Fundraising is increasing while valuations are sky-high and exits are on the decline — a sign, market observers say, that the PE market is nearing the end of its cycle.
Institutional Investor

What's different? Jessica Livingston shares a list of things that she thinks are different about unicorns.
Founders at Work

Making culture a tangible metric. Investing time in building culture doesn't pay off in the short term, so it's often discounted.
Y Combinator
If you loved this newsletter, send it to a friend.
If you hated it, send it to an enemy.
All the data in this newsletter comes from CB Insights. Join NEA, Cisco & hundreds of other clients and get access to the industry's best private company data.

Sign up for access.
Copyright © 2017 CB Information Services, All rights reserved.
498 7th ave, 17th floor, New York, NY 10018